In general, anti-IL6 agents appear to be effective against medium to severe cases of COVID-19, increasing CD8+ T-cell frequency and functionalities, preventing multi-organ failure, reducing inflammation levels, and, thus, reducing the risk of mortality [24]. This evidence concerns the gene IL6 and COVID-19.